TABLE 3.
Details of examinations and follow‐up of the patients
| Patient No. | CK level (U/L) a | EMG | MRI | Muscle biopsy | Nerve biopsy | Treatment | Follow‐up |
|---|---|---|---|---|---|---|---|
| 1 | 353.9 | M/N (decreased MCV) | NA | IFSV + A + R + I + LP | Levocarnitine (2.0 g/d) | PD | |
| 2 | 282.8 | N | NA | IFSV + A + D + R + HC + IN | Vitamin B1 (60.0 mg/d) | PD | |
| 3 | 243.1 | M/N (decreased MCV) | NA | IFSV + D + R + HC + ME + HM | Swelling and loss of myelinated fibre; axonal degeneration | Vitamin B1 (60.0 mg/d), Mecobalamin (1.5 mg/d) | PD |
| 4 | 165.3 | M | NA | IFSV + A + D + R + HC + HM + IN + LP | Adenosine disodium triphosphate (60.0 mg/d) | SD | |
| 5 | 244.7 | M | Multiple abnormal signals in femoral shaft and extensively increased signals in left hamstrings | IFSV + R + HC + ME | Levocarnitine (2.0 g/d), adenosine Disodium triphosphate (60.0 mg/d) | PD | |
| 6 | 249.0 | M/N | Fatty infiltration and muscle atrophy | IFSV + I + LP | None | NA | |
| 7 | 354.8 | M | NA | IFSV + A + D + R + I | Levocarnitine (2.0 g/d) | PD | |
| 8 | 1277.0 | M | Diffuse oedema and swelling of multiple calf muscles | IFSV + D + R + HC | Adenosine disodium triphosphate (60.0 mg/d), Vitamin B1 (60.0 mg/d) | NA | |
| 9 | 229.1 | M | NA | IFSV + R + HC + HM + LP | Adenosine disodium triphosphate (60.0 mg/d) | PD | |
| 10 | 542.1 | M/N | NA | IFSV + A + D + R + I + HC + HM + LP | None | NA |
Abbreviations: M, myogenic lesion; N, neurogenic lesion; M/N, myogenic lesion accompanied with neurogenic lesion; MCV, motor nerve conduction velocity; NA, not available; IFSV, increased fibre size variation; A, atrophic myofibre; D, degenerative, necrotic and regenerative myofibre; R, rimmed vacuoles; I, inflammatory infiltration; HC, hyperplasia of connective tissue; ME, moth‐eaten myofibre; HM, hypertrophic myofibre; IN, internal nuclei; LP, lipid droplets; PD, progressive disease; SD, stable disease; None, refusal to any treatment.
a
Reference value of CK: 40.0–200.0 U/L.